#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15412	16S	1529	1529	100.0	16S.l15.c17.ctg.2	2214	829.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1439	1439	C	947	C,T,A	944,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15412	16S	1529	1529	100.0	16S.l15.c17.ctg.2	2214	829.0	0	HET	.	.	.	C260T,A	.	260	260	C	515	515	C	854	C,T,A	680,172,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26254	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4080	801.5	0	.	n	.	0	T695C	SNP	695	695	T	1228	1228	C	910	C,G,T	905,4,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26254	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4080	801.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1870	1870	A	1046	A	1045	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26254	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4080	801.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2504	2504	C	940	C,T	939,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26254	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4080	801.5	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3130	3130	T	905	T,C,G	902,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26254	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4080	801.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2578	2578	A	884	A	884	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2274	folP	852	852	100.0	folP.l15.c4.ctg.1	2035	139.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1230	1232	AGC	224;229;228	A,C;G;C	223,1;229;228	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5838	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3836	189.5	1	SNP	p	S91F	0	.	.	271	273	TCC	778	780	TCC	222;223;220	T;C;C,G	222;223;219,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5838	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3836	189.5	1	SNP	p	D95G	0	.	.	283	285	GAC	790	792	GAC	225;223;224	G;A,G;C	225;222,1;224	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5838	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3836	189.5	1	SNP	p	D95N	0	.	.	283	285	GAC	790	792	GAC	225;223;224	G;A,G;C	225;222,1;224	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	2156	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1555	170.4	1	SNP	p	G45D	1	.	.	133	135	GAC	581	583	GAC	253;255;257	G;A;C	253;255;257	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1208	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1477	101.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5390	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3435	195.2	1	SNP	p	D86N	0	.	.	256	258	GAC	804	806	GAC	238;236;236	G;A,T;C	237;235,1;236	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5390	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3435	195.2	1	SNP	p	S87I	0	.	.	259	261	AGT	807	809	AGT	232;234;236	A,C,T,G;G;T,A	229,1,1,1;234;235,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5390	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3435	195.2	1	SNP	p	S87W	0	.	.	259	261	AGT	807	809	AGT	232;234;236	A,C,T,G;G;T,A	229,1,1,1;234;235,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5390	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3435	195.2	1	SNP	p	S87R	0	.	.	259	261	AGT	807	809	AGT	232;234;236	A,C,T,G;G;T,A	229,1,1,1;234;235,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5390	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3435	195.2	1	SNP	p	S88P	0	.	.	262	264	TCC	810	812	TCC	239;238;239	T;C,G,A;C	239;234,2,2;238	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4536	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3084	183.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1776	1778	GGC	235;237;238	G;G;C	235;237;238	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2903	174.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1455	1457	GCA	234;234;232	G,A,T;C,G,A;A,C	232,1,1;232,1,1;231,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2903	174.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1458	1460	ATC	232;235;239	A,T;T,C;C	231,1;233,2;239	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2903	174.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1470	1472	GTG	236;236;235	G,C;T;G	235,1;236;235	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2903	174.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1470	1472	GTG	236;236;235	G,C;T;G	235,1;236;235	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2903	174.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1974	1976	ACC	206;205;208	A;C;C	206;204;207	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2903	174.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2028	2030	GCG	214;214;215	G;C,T;G	214;213,1;215	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2903	174.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2028	2030	GCG	214;214;215	G;C,T;G	214;213,1;215	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2903	174.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2151	2153	GGC	238;238;239	G;G;C	238;238;239	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2903	174.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2160	2162	GGC	235;237;236	G;G;C,T	235;237;235,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2903	174.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2178	2180	CCG	245;246;242	C,G,A;C,A;G	242,2,1;245,1;242	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5738	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	3355	212.1	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1741	1743	CTG	238;241;243	C;T;G	238;241;243	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2814	porA	1146	1146	99.83	porA.l15.c30.ctg.1	2437	143.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	862	862	C	203	C	203	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	G38E	NONSYN	112	114	GGA	591	593	GAA	249;249;251	G,C;A;A,T	248,1;249;250,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	621	623	GGA	248;249;252	G;G;A	248;249;252	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	T87A	NONSYN	259	261	ACT	738	740	GCT	243;243;241	G,A;C;T	242,1;243;241	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	T89S	NONSYN	265	267	ACC	744	746	AGC	238;236;235	A;G,C;C	238;235,1;235	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	.	MULTIPLE	358	359	AA	836	837	CG	200;204	C;G	200;204	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	.	MULTIPLE	361	362	GA	839	841	CAG	205;204;205	C;A;G	205;204;205	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	N122K	NONSYN	364	366	AAC	843	845	AAA	204;205;207	A;A;A	204;205;206	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	K143E	NONSYN	427	429	AAA	906	908	GAA	230;231;233	G;A;A	230;231;233	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	V151A	NONSYN	451	453	GTA	930	932	GCA	260;257;258	G;C;A,G	260;257;257,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	N212D	NONSYN	634	636	AAT	1113	1115	GAT	246;243;240	G,A;A,C;T	245,1;241,2;240	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	D213G	NONSYN	637	639	GAT	1116	1118	GGT	238;234;234	G,A,C;G,A;T	235,2,1;233,1;234	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1131	1133	ATG	224;221;223	A;T,C;G,C,T	224;220,1;220,2,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1245	1247	GCA	216;213;212	G;C,G;A	216;212,1;212	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1248	1250	ACG	212;213;218	A;CGGGGG,CGGGG;G,C	212;200,1;217,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	R258G	NONSYN	772	774	CGT	1251	1253	GGG	222;224;225	G;G;G,A	221;223;222,2	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1254	1256	GTT	227;227;225	G,T,C;T,G,A;T	224,1,1;225,1,1;225	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1314	1316	GTA	238;238;237	G,T;T,G,A;A,T	237,1;236,1,1;236,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1353	1355	ACT	254;253;257	A,T;C;T	253,1;253;257	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1359	1361	GAT	261;264;263	G,C;A,T;T	259,2;263,1;263	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1371	1373	CAC	269;273;276	C,T;A,T;C	267,2;272,1;276	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	1	SNP	p	G120K	1	.	.	358	360	AAG	836	838	CGG	200;204;203	C;G;G,T	200;204;202,1	porB1b.WHO_Z_02266c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	1	SNP	p	D121N	0	.	.	361	363	GAC	839	842	CGC	205;205;209	C;G;C	205;205;208	porB1b.WHO_Z_02266c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2830	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1695	207.2	1	SNP	p	A121D	1	.	.	361	363	GAC	839	842	CGC	205;205;209	C;G;C	205;205;208	porB1b.WHO_Z_02266c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9978	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5300	234.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2198	2200	AAT	284;282;280	A;A,G;T,G	284;281,1;279,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1402	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1319	131.9	1	SNP	p	V57M	1	.	.	169	171	ATG	672	674	ATG	246;249;251	A;T;G	246;249;251	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
